{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:07:42Z","timestamp":1771560462913,"version":"3.50.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,7,11]],"date-time":"2007-07-11T00:00:00Z","timestamp":1184112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s00115-007-2310-4","type":"journal-article","created":{"date-parts":[[2007,7,17]],"date-time":"2007-07-17T02:15:51Z","timestamp":1184638551000},"page":"17-35","source":"Crossref","is-referenced-by-count":7,"title":["Pharmakotherapie bei Schizophrenie und komorbider Substanzst\u00f6rung","Pharmacotherapy of schizophrenia and comorbid substance use disorder"],"prefix":"10.1007","volume":"79","author":[{"given":"T.","family":"Wobrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"D\u2019Amelio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Falkai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,7,11]]},"reference":[{"key":"2310_CR1","first-page":"780","volume":"151","author":"Albanese","year":"1994","unstructured":"Albanese MJ, Khantzian EJ, Murphy SL, Green AI (1994) Decreased substance use in chronically psychotic patients treated with clozapine. Am J Psychiatry 151: 780\u2013781; letter","journal-title":"Am J Psychiatry"},{"key":"2310_CR2","first-page":"572","volume":"20","author":"Ballenger","year":"1984","unstructured":"Ballenger JC, Post RM (1984) Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull 20: 572\u2013584","journal-title":"Psychopharmacol Bull"},{"key":"2310_CR3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.jcp.0000169419.38899.5b","volume":"25","author":"Beresford","year":"2005","unstructured":"Beresford TP, Clapp L, Martin B, Wiberg JL (2005) Aripiprazole in schizophrenia with cocaine dependence. A pilot study. J Clin Psychopharmacol 25: 363\u2013366","journal-title":"J Clin Psychopharmacol"},{"key":"2310_CR4","first-page":"177","volume":"14","author":"Berk","year":"1999","unstructured":"Berk M, Brook S, Trandafir AI (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 14: 177\u2013180","journal-title":"Int Clin Psychopharmacol"},{"key":"2310_CR5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3109\/13651500009177999","volume":"4","author":"Berk","year":"2000","unstructured":"Berk M, Brook S, Nur F (2000) Risperidone compared to haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int J Psych Clin Pract 4: 139\u2013142","journal-title":"Int J Psych Clin Pract"},{"key":"2310_CR6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/schbul\/16.1.81","volume":"16","author":"Bowers","year":"1990","unstructured":"Bowers MB Jr, Mazure CM, Nelson JC, Jatlow PI (1990) Psychotogenic drug use and neuroleptic response. Schizophr Bull 16: 81\u201385","journal-title":"Schizophr Bull"},{"key":"2310_CR7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/01.jcp.0000085412.08426.08","volume":"23","author":"Brown","year":"2003","unstructured":"Brown ES, Nejtek VA, Perantie DC et al. (2003) Cocaine and amphetamine use in patients wih psychiatric illness. A randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol 23: 384\u2013388","journal-title":"J Clin Psychopharmacol"},{"key":"2310_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1176\/ajp.151.3.385","volume":"151","author":"Buckley","year":"1994","unstructured":"Buckley P, Thompson PA, Way L, Meltzer HY (1994) Substance use among patients with treatment-resistant schizophrenia: characteristics and implication for clozapine therapy. Am J Psychiatry 151: 385\u2013389","journal-title":"Am J Psychiatry"},{"key":"2310_CR9","unstructured":"Buckley P, Thompson PA, Way L, Meltzer HY (1994) Substance use and clozapine treatment. J Clin Psychiatry [Suppl B] 55: 114\u2013116"},{"key":"2310_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0920-9964(00)00114-6","volume":"48","author":"Cantor-Graae","year":"2001","unstructured":"Cantor-Graae E, Nordstrom LG, McNeil TF (2001) Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 48: 69\u201382","journal-title":"Schizophr Res"},{"key":"2310_CR11","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF02249430","volume":"32","author":"Carey","year":"1996","unstructured":"Carey KB (1996) Substance use reduction in the context of outpatient psychiatric treatment: a collaborative, motivational, harm reduction approach. Com Ment Health J 32: 291\u2013306","journal-title":"Com Ment Health J"},{"key":"2310_CR12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0006-3223(01)01134-9","volume":"50","author":"Chambers","year":"2001","unstructured":"Chambers RA, Krystal JH, Self DW (2001) A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 50: 71\u201383","journal-title":"Biol Psychiatry"},{"key":"2310_CR13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1176\/ajp.147.10.1374","volume":"147","author":"Cohen","year":"1990","unstructured":"Cohen LJ, Test MA, Brown RJ (1990) Suicide and schizophrenia: Data from a prospective community treatment study. Am J Psychiatry 147: 602\u2013607","journal-title":"Am J Psychiatry"},{"key":"2310_CR14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0920-9964(98)00062-0","volume":"33","author":"Conley","year":"1998","unstructured":"Conley RR, Kelly DL, Gale EA (1998) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 33: 95\u2013101","journal-title":"Schizophr Res"},{"key":"2310_CR15","doi-asserted-by":"crossref","unstructured":"Deutsche Gesellschaft f\u00fcr Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Hrsg) (2006) S3 \u2013 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1, Behandlungsleitlinie Schizophrenie. Leitlinienprojektgruppe: W. Gaebel (federf\u00fchrend), P. Falkai, S. Weinmann, T. Wobrock. Steinkopff, Darmstadt","DOI":"10.1024\/1661-4747.54.1.3"},{"key":"2310_CR16","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2105\/AJPH.86.7.973","volume":"86","author":"Dickey","year":"1996","unstructured":"Dickey B, Azeni H (1996) Persons with dual diagnosis of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Pub Health 86: 973\u2013977","journal-title":"Am J Pub Health"},{"key":"2310_CR17","first-page":"224","volume":"14","author":"Dixon","year":"1991","unstructured":"Dixon L, Haas G, Weiden PJ et al. (1991) Drug abuse in schizophrenic patients: Clinical correlates and reasons for use. Am J Psychiatry 14: 224\u2013230","journal-title":"Am J Psychiatry"},{"key":"2310_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.schbul.a033429","volume":"26","author":"Drake","year":"2000","unstructured":"Drake RE, Mueser KT (2000) Psychosocial approaches to dual diagnosis. Schizophr Bull 26: 105\u2013118","journal-title":"Schizophr Bull"},{"key":"2310_CR19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.schbul.a033464","volume":"26","author":"Drake","year":"2000","unstructured":"Drake RE, Xie H, McHugo GJ, Green AI (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 26: 441\u2013449","journal-title":"Schizophr Bull"},{"key":"2310_CR20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1176\/ajp.134.4.471-a","volume":"134","author":"Ewing","year":"1977","unstructured":"Ewing JA, Meuller RA, Rouse BA, Silver D (1977) Low levels of dopamine-beta-hydroxylase and psychosis. Am J Psychiatry 134: 927\u2013928","journal-title":"Am J Psychiatry"},{"key":"2310_CR21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","volume":"6","author":"Falkai","year":"2005","unstructured":"Falkai P, Wobrock T, Lieberman J et al. (2005) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6: 132\u2013191","journal-title":"World J Biol Psychiatry"},{"key":"2310_CR22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0376-8716(99)00114-3","volume":"59","author":"Farren","year":"2000","unstructured":"Farren CK, Hameedi FA, Rosen MA et al. (2000) Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend 59: 153\u2013163","journal-title":"Drug Alcohol Depend"},{"key":"2310_CR23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF00172886","volume":"90","author":"Gawin","year":"1986","unstructured":"Gawin FH (1986) Neuroleptic reduction of cocaine-induced paranoia but not euphoria? Psychopharmacology 90: 142\u2013143","journal-title":"Psychopharmacology"},{"key":"2310_CR24","first-page":"344","volume":"56","author":"George","year":"1995","unstructured":"George T, Sernyak M, Ziedonis D, Woods SW (1995) Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 56: 344\u2013346","journal-title":"J Clin Psychiatry"},{"key":"2310_CR25","first-page":"398","volume":"2","author":"Gold","year":"1978","unstructured":"Gold MS, Donabedian RK, Dillard M et al. (1978) Antipsychotic effect opiate agonists. Lancet 2: 398\u2013399","journal-title":"Lancet"},{"key":"2310_CR26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00115-004-1692-9","volume":"75","author":"Gouzoulis-Mayfrank","year":"2004","unstructured":"Gouzoulis-Mayfrank E (2004) Doppeldiagnose Psychose und Sucht. Von den Grundlagen zur Praxis. Nervenarzt 75: 642\u2013650","journal-title":"Nervenarzt"},{"key":"2310_CR27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0920-9964(02)00231-1","volume":"60","author":"Green","year":"2003","unstructured":"Green AI, Burgess ES, Dawson R et al. (2003) Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res 60: 81\u201385","journal-title":"Schizophr Res"},{"key":"2310_CR28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2003.08.001","volume":"66","author":"Green","year":"2004","unstructured":"Green AI, Tohen MF, Hamer RM et al. (2004) First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 66: 125\u2013135","journal-title":"Schizophr Res"},{"key":"2310_CR29","unstructured":"Green AI (2005) Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J Clin Psychiatry [Suppl 6] 66: 21\u201326"},{"key":"2310_CR30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1177\/070674370104600919","volume":"46","author":"Gupta","year":"2001","unstructured":"Gupta N, Basu D (2001) Does risperidon reduce concomitant substance abuse in cases of schizophrenia? Can J Psychiatry 46: 862\u2013863","journal-title":"Can J Psychiatry"},{"key":"2310_CR31","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1176\/ajp.152.6.856","volume":"152","author":"Haywood","year":"1995","unstructured":"Haywood TW, Kravitz HM, Grossman LS et al. (1995) Predicting the \u201erevolving door\u201c phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 152: 856\u2013861","journal-title":"Am J Psychiatry"},{"key":"2310_CR32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/0269881105051542","volume":"19","author":"Kalyoncu","year":"2005","unstructured":"Kalyoncu A, Mirsal H, Pektas O et al. (2005) Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol 19: 301\u2013305","journal-title":"J Psychopharmacol"},{"key":"2310_CR33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/070674370304800208","volume":"48","author":"Kelly","year":"2003","unstructured":"Kelly DL, Gale EA, Conley RR (2003) Clozapine treatment in patients with prior substance abuse. Can J Psychiatry 48: 111\u2013114","journal-title":"Can J Psychiatry"},{"key":"2310_CR34","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/ajp.143.7.867","volume":"143","author":"Kofoed","year":"1986","unstructured":"Kofoed L, Kania J, Walsh T, Atkinson RM (1986) Outpatient treatment of patients with substance abuse and coexisting psychiatric disorders. Am J Psychiatry 143: 867\u2013872","journal-title":"Am J Psychiatry"},{"key":"2310_CR35","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/00952998809001555","volume":"14","author":"Kosten","year":"1988","unstructured":"Kosten TR, Kleber HD (1988) Rapid death during cocain abuse: variant of the neuroleptic malignant syndrome? Am J Drug Alcohol Abuse 14: 335\u2013346","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2310_CR36","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/schbul\/23.2.195","volume":"23","author":"Kovasznay","year":"1997","unstructured":"Kovasznay B, Fleischer J, Tanenberg-Karant M et al. (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23: 195\u2013201","journal-title":"Schizophr Bull"},{"key":"2310_CR37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR et al. (2002) Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63: 892\u2013909","journal-title":"J Clin Psychiatry"},{"key":"2310_CR38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1177\/070674379804300705","volume":"43","author":"Lee","year":"1998","unstructured":"Lee ML, Dickson RA, Campbell M et al. (1998) Clozapine and substance abuse in patients with schizophrenia. Can J Psychiatry 43: 855\u2013856; letter","journal-title":"Can J Psychiatry"},{"key":"2310_CR39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/00952999809016902","volume":"24","author":"Levin","year":"1998","unstructured":"Levin RF, Evans SM, Coomaraswammy S et al. (1998) Flupentixol treatment for cocaine abusers with schizophrenia: a pilot study. Am J Drug Alcohol Abuse 24: 343\u2013360","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2310_CR40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archpsyc.1994.03950040017002","volume":"51","author":"Linszen","year":"1994","unstructured":"Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51: 273\u2013279","journal-title":"Arch Gen Psychiatry"},{"key":"2310_CR41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0740-5472(01)00205-7","volume":"21","author":"Littrell","year":"2001","unstructured":"Littrell KH, Petty RG, Hilligoss NM et al. (2001) Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 21: 217\u2013221","journal-title":"J Subst Abuse Treat"},{"key":"2310_CR42","first-page":"337","volume":"14","author":"Major","year":"1978","unstructured":"Major LF, Lerner P, Ballenger JC et al. (1978) Dopamine-\u03b2-hydroxylase in the cerebrospinal fluid: relationship to disulfiram-induced psychosis. Biol Psychiatry 14: 337\u2013343","journal-title":"Biol Psychiatry"},{"key":"2310_CR43","first-page":"959","volume":"152","author":"Marcus","year":"1995","unstructured":"Marcus P, Snyder R (1995) Reduction of comorbid substance abuse with clozapine. Am J Psychiatry 152: 959; letter","journal-title":"Am J Psychiatry"},{"key":"2310_CR44","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1300\/J069v19n03_05","volume":"19","author":"Maxwell","year":"2000","unstructured":"Maxwell S, Shinderman MS (2000) Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Dis 19: 61\u201369","journal-title":"J Addict Dis"},{"key":"2310_CR45","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/00005053-199512000-00006","volume":"183","author":"McHugo","year":"1995","unstructured":"McHugo GJ, Drake RE, Burton HL, Ackerson TH (1995) A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis 183: 762\u2013767","journal-title":"J Nerv Ment Dis"},{"key":"2310_CR46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/schbul\/16.1.31","volume":"16","author":"Mueser","year":"1990","unstructured":"Mueser KT, Yarnold PR, Levinson DR et al. (1990) Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull 16: 31\u201356","journal-title":"Schizophr Bull"},{"key":"2310_CR47","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4603(98)00073-2","volume":"23","author":"Mueser","year":"1998","unstructured":"Mueser KT, Drake RE, Wallach MA (1998) Dual diagnosis: A review of etiological theories. Addict Behav 23: 717\u2013734","journal-title":"Addict Behav"},{"key":"2310_CR48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1521-0391.2003.tb00652.x","volume":"12","author":"Mueser","year":"2003","unstructured":"Mueser KT, Noordsy DL, Fox L, Wolfe R (2003) Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 12: 242\u2013252","journal-title":"Am J Addict"},{"key":"2310_CR49","unstructured":"National Institute for Clinical Excellence (2003) Core interventions in the treatment of schizophrenia. NICE, London; www.nice.org.uk"},{"key":"2310_CR50","unstructured":"Noordsy DL, O\u2018Keefe C (1999) Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry [Suppl 19] 60: 47\u201351"},{"key":"2310_CR51","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1176\/appi.ps.52.4.501","volume":"52","author":"Noordsy","year":"2001","unstructured":"Noordsy DL, O\u2018Keefe C, Mueser KT, Xie H (2001) Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 52: 501\u2013507","journal-title":"Psychiatr Serv"},{"key":"2310_CR52","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11920-003-0066-5","volume":"5","author":"Noordsy","year":"2003","unstructured":"Noordsy DL, Green AI (2003) Pharmacotherapy for schizophrenia and co-occuring substance use disorders. Curr Psychiatry Rep 5: 340\u2013346","journal-title":"Curr Psychiatry Rep"},{"key":"2310_CR53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/00952999009001572","volume":"16","author":"Olivera","year":"1990","unstructured":"Olivera AA, Kiefer MW, Manley NK (1990) Tardive dyskinesia in psychiatric patients with substance abuse. Am J Alcohol Abuse 16: 57\u201366","journal-title":"Am J Alcohol Abuse"},{"key":"2310_CR54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1022461026275","volume":"33","author":"Owen","year":"1997","unstructured":"Owen C, Rutherford V, Jones M et al. (1997) Noncompliance in psychiatric aftercare. Com Ment Health J 33: 25\u201334","journal-title":"Com Ment Health J"},{"key":"2310_CR55","doi-asserted-by":"crossref","unstructured":"Petrakis IL, O\u2019Malley S, Rounsaville B et al. (2004) Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl) 172: 291\u2013297","DOI":"10.1007\/s00213-003-1658-9"},{"key":"2310_CR56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/10550490500419052","volume":"15","author":"Petrakis","year":"2006","unstructured":"Petrakis IL, Leslie D, Finney JW, Rosenheck R (2006) Atypical antipsychotic medication and substance use-related outcomes in the treatment of schizophrenia. Am J Addict 15: 44\u201349","journal-title":"Am J Addict"},{"key":"2310_CR57","first-page":"121","volume":"18","author":"Potvin","year":"2003","unstructured":"Potvin S, Stip E, Roy JY (2003) Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 18: 121\u2013132","journal-title":"Int Clin Psychopharmacol"},{"key":"2310_CR58","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/070674370404901020","volume":"49","author":"Potvin","year":"2004","unstructured":"Potvin S, Stip E, Roy JY (2004) The effect of quetiapine on cannabis use in 8 psychosis patients with drug dependency. Can J Psychiatry 49: 711","journal-title":"Can J Psychiatry"},{"key":"2310_CR59","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1185\/030079906X112561","volume":"22","author":"Potvin","year":"2006","unstructured":"Potvin S, Stip E, Lipp O et al. (2006) Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 22: 1277\u20131285","journal-title":"Curr Med Res Opin"},{"key":"2310_CR60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/oxfordjournals.schbul.a033338","volume":"24","author":"Rasanen","year":"1998","unstructured":"Rasanen P, Tiihonen J, Isohanni M et al. (1998) Schizophrenia, alcohol abuse, and violent behavior: A 26\u00a0year follow-up Study of an unselected birth cohort. Schizophr Bull 24: 437\u2013441","journal-title":"Schizophr Bull"},{"key":"2310_CR61","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","volume":"264","author":"Regier","year":"1990","unstructured":"Regier DA, Farmer ME, Rae DS et al. (1990) Comorbidity of mental disorders with alcohol and other drug abuse: Results form the Epidemiologic Catchment Area (ECA) Study. JAMA 264: 2511\u20132518","journal-title":"JAMA"},{"key":"2310_CR62","first-page":"79","volume":"46","author":"Richard","year":"1985","unstructured":"Richard ML, Liskow BI, Perry PJ (1985) Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 46: 79\u201383","journal-title":"J Clin Psychiatry"},{"key":"2310_CR63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11920-005-0082-8","volume":"7","author":"Roth","year":"2005","unstructured":"Roth RM, Brunette MF, Green AI (2005) Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Curr Psychiatry Rep 7: 283\u2013291","journal-title":"Curr Psychiatry Rep"},{"key":"2310_CR64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/070674370605100808","volume":"51","author":"Rubio","year":"2006","unstructured":"Rubio G, Martinez I, Ponce G et al. (2006) Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 51: 531\u2013539","journal-title":"Can J Psychiatry"},{"key":"2310_CR65","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.nmd.0000165089.14736.bf","volume":"Dis193","author":"Sayers","year":"2005","unstructured":"Sayers SL, Campbell EC, Kondrich J et al. (2005) Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis193: 379\u2013386","journal-title":"J Nerv Ment"},{"key":"2310_CR66","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1081\/ADA-120023458","volume":"29","author":"Scheller-Gilkey","year":"2003","unstructured":"Scheller-Gilkey G, Woolwine BJ, Cooper I et al. (2003) Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics. Am J Drug Alcohol Abuse 29: 553\u2013566","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2310_CR67","unstructured":"Schilkrut R, Cabrera J, Morales E, Herrera L (1998) Neuroleptics in the treatment of drug dependence in schizophrenics. A study with flupenthixol decanoate. Psychopharmacology [Suppl 96]: 342 (Abstr 33.01.50)"},{"key":"2310_CR68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00005053-199301000-00006","volume":"181","author":"Seibyl","year":"1993","unstructured":"Seibyl JP, Satel SL, Anthony D et al. (1993) Effects of cocaine on hospital course in schizophrenia. J Nerv Ment Dis 181: 31\u201337","journal-title":"J Nerv Ment Dis"},{"key":"2310_CR69","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00004714-199806000-00011","volume":"18","author":"Sernyak","year":"1998","unstructured":"Sernyak MJ, Glazer WM, Heninger GR et al. (1998) Naltrexone augmentation of neuroleptics in schizophrenia. J Clin Psychopharmacol 18: 248\u2013251","journal-title":"J Clin Psychopharmacol"},{"key":"2310_CR70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/schbul\/16.1.111","volume":"16","author":"Siris","year":"1990","unstructured":"Siris SG (1990) Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 16: 111\u2013122","journal-title":"Schizophr Bull"},{"key":"2310_CR71","first-page":"127","volume":"29","author":"Siris","year":"1993","unstructured":"Siris SG, Mason SE, Bermanzohn PC et al. (1993) Dual diagnosis\/psychiatric comorbidity of drug dependence: epidemiology and treatment. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull 29: 127\u2013133","journal-title":"Psychopharmacol Bull"},{"key":"2310_CR72","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/070674370204700710","volume":"47","author":"Smelson","year":"2002","unstructured":"Smelson DA, Losonczy MF, Davis CW et al. (2002) Risperidone decreases craving and relapses in individuals with schizophrenia and cocain dependence. Can J Psychiatry 47: 671\u2013675","journal-title":"Can J Psychiatry"},{"key":"2310_CR73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.jcp.0000194624.07611.5e","volume":"26","author":"Smelson","year":"2006","unstructured":"Smelson DA, Ziedonis D, Williams J et al. (2006) The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 26: 9\u201312","journal-title":"J Clin Psychopharmacol"},{"key":"2310_CR74","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-0447.1991.tb03143.x","volume":"84","author":"Soni","year":"1991","unstructured":"Soni SD, Brownlee M (1991) Alcohol abuse in chronic schizophrenics: implications for management in the community. Acta Psychiatr Scand 84: 272\u2013276","journal-title":"Acta Psychiatr Scand"},{"key":"2310_CR75","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF02190250","volume":"242","author":"Soyka","year":"1993","unstructured":"Soyka M, Albus M, Kathmann N et al. (1993) Prevalence of alcohol and drug abuse in schizophrenia inpatients. Eur Arch Psychiatry Clin Neurosci 242: 362\u2013272","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2310_CR76","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1055\/s-2007-979591","volume":"28","author":"Soyka","year":"1995","unstructured":"Soyka M, Sand P (1995) Successful treatment with flupenthixol decanoate of a patient with both schizophrenia and alcoholism. Pharmacopsychiatry 28: 64\u201365","journal-title":"Pharmacopsychiatry"},{"key":"2310_CR77","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2165\/00023210-199605060-00002","volume":"5","author":"Soyka","year":"1996","unstructured":"Soyka M (1996) Dual diagnosis in patients with schizophrenia. Issues in pharmacological treatment. CNS Drugs 5: 414\u2013425","journal-title":"CNS Drugs"},{"key":"2310_CR78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000068809","volume":"9","author":"Soyka","year":"2003","unstructured":"Soyka M, Aichm\u00fcller C, Bardeleben U von et al. (2003) Flupenthixol in relapse prevention in schizophrenics with comorbid alcoholism: results from an open clinical study. Eur Addict Res 9: 65\u201372","journal-title":"Eur Addict Res"},{"key":"2310_CR79","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-9964(95)00068-2","volume":"20","author":"Swofford","year":"1996","unstructured":"Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB (1996) Substance use: A powerful predictor of relapse in schizophrenia. Schizophr Res 20: 145\u2013151","journal-title":"Schizophr Res"},{"key":"2310_CR80","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.4088\/JCP.v63n1214c","volume":"63","author":"Tsuang","year":"2002","unstructured":"Tsuang J, Marder SR, Han A, Hsieh W (2002) Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 63: 1180\u20131181; letter","journal-title":"J Clin Psychiatry"},{"key":"2310_CR81","first-page":"629","volume":"22","author":"Tsuang","year":"2002","unstructured":"Tsuang J, Eckman T, Marder SR, Tucker D (2002) Can risperidone reduce cocaine use in substance abusing schizophrenic patients? J Clin Psychiatry 22: 629\u2013630; letter","journal-title":"J Clin Psychiatry"},{"key":"2310_CR82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2190\/WM5V-D9Y2-2HYW-VGWX","volume":"33","author":"Weisman","year":"2003","unstructured":"Weisman RL (2003) Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report. Int J Psychiatry Med 33: 85\u201389","journal-title":"Int J Psychiatry Med"},{"key":"2310_CR83","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/schbul\/23.2.215","volume":"23","author":"Wilkins","year":"1997","unstructured":"Wilkins JN (1997) Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophr Bull 23: 215\u2013228","journal-title":"Schizophr Bull"},{"key":"2310_CR84","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1055\/s-2004-818454","volume":"72","author":"Wobrock","year":"2004","unstructured":"Wobrock T, Falkai P, Pajonk FG (2004) Akuttherapie der Schizophrenie. Fortschr Neurol Psychiatr 72: 705\u2013726","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2310_CR85","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-2005-919171","volume":"31","author":"Wobrock","year":"2005","unstructured":"Wobrock T, Pajonk FG, D\u2018Amelio R, Falkai P (2005) Schizophrenie und Sucht. PsychoNeuro 31: 433\u2013440","journal-title":"PsychoNeuro"},{"key":"2310_CR86","first-page":"309","volume":"28","author":"Ziedonis","year":"1992","unstructured":"Ziedonis DM, Richardson T, Lee E et al. (1992) Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. Psychopharmacol Bull 28: 309\u2013314","journal-title":"Psychopharmacol Bull"},{"key":"2310_CR87","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00131746-200509000-00005","volume":"11","author":"Ziedonis","year":"2005","unstructured":"Ziedonis DM, Smelson D, Rosenthal RN et al. (2005) Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 11: 315\u2013339","journal-title":"J Psychiatr Pract"},{"key":"2310_CR88","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00004714-200002000-00016","volume":"20","author":"Zimmet","year":"2000","unstructured":"Zimmet S, Strous RD, Burgess E et al. (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol 20: 94\u201398","journal-title":"J Clin Psychopharmacol"},{"key":"2310_CR89","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/ajp.156.7.1119a","volume":"156","author":"Tsuang","year":"1999","unstructured":"Tsuang J, Eckman TE, Shaner A, Marder SR (1999) Clozapine for substance-abusing schizophrenic patientes. Am J Psychiatry 156: 1119\u20131120 (letter)","journal-title":"Am J Psychiatry"},{"key":"2310_CR90","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00005053-199410000-00017","volume":"182","author":"Yovell","year":"1994","unstructured":"Yovell Y, Opler LA (1994) Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypotheses. J Nerv Ment Dis 182: 591\u2013592 (letter)","journal-title":"J Nerv Ment Dis"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-007-2310-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-007-2310-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-007-2310-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T11:34:57Z","timestamp":1683977697000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-007-2310-4"}},"subtitle":["Eine systematische \u00dcbersicht","A systematic review"],"short-title":[],"issued":{"date-parts":[[2007,7,11]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["2310"],"URL":"https:\/\/doi.org\/10.1007\/s00115-007-2310-4","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,11]]}}}